Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors

Next Previous
Trial Profile

Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
  • Indications Anal cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Merkel cell carcinoma; Nasopharyngeal cancer; Oesophageal cancer; Penile cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CheckMate-358
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical

Most Recent Events

  • 21 Oct 2023 This trail has been completed in Spain according to European Clinical Trials Database record.
  • 06 Jun 2023 Results (n=68) assessing the efficacy and safety of nivolumab with or without ipilimumab in patients with recurrent/metastatic Merkel cell carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 12 Dec 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top